Related Experiment Video
Updated: May 7, 2026
09:21
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Edaravone for acute stroke: Meta-analyses of data from randomized controlled trials
Jie Yang1,2, Xiaoyang Cui1, Jie Li1,3
1a Department of Neurology , West China Hospital, Sichuan University , Chengdu , PR China .
Developmental Neurorehabilitation
|October 4, 2013
Summary
Edaravone shows promise in improving neurological function after acute ischemic stroke and intracerebral hemorrhage. However, evidence for reducing long-term death or disability remains inconclusive.
Area of Science:
- Neurology
- Pharmacology
- Clinical Medicine
Background:
- Acute stroke, encompassing ischemic stroke and intracerebral hemorrhage, represents a significant cause of mortality and long-term disability worldwide.
- Edaravone, a free radical scavenger, has been investigated for its neuroprotective effects in various stroke models.
Purpose of the Study:
- To systematically evaluate the efficacy of edaravone in treating patients with acute ischemic stroke and intracerebral hemorrhage.
- To assess edaravone's impact on mortality, long-term disability, and short-term neurological impairment.
Main Methods:
- A systematic review and meta-analysis of randomized controlled trials (RCTs) were conducted.
- Comprehensive literature searches were performed to identify relevant studies.
- Cochrane methods for systematic reviews were adhered to throughout the process.
Main Results:
- Edaravone significantly improved short-term neurological impairment in acute ischemic stroke (AIS) (MD = 7.09; 95% CI, 5.12 to 9.05).
- Edaravone also improved short-term neurological impairment in intracerebral hemorrhage (ICH) (MD = -4.32; 95% CI, -5.35 to -3.29).
- While initial analysis suggested edaravone reduced death or long-term disability in AIS (RR = 0.65; 95% CI, 0.48 to 0.89), sensitivity analysis yielded conflicting results.
Conclusions:
- Edaravone demonstrates a benefit in improving neurological impairment for both acute ischemic stroke and intracerebral hemorrhage.
- Current evidence is insufficient to conclusively state that edaravone reduces death or long-term disability in patients with AIS or ICH.
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:17Hemorrhagic Stroke l: Introduction
A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...